Compare VRAX & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | DSS |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 5.5M |
| IPO Year | 2021 | 2020 |
| Metric | VRAX | DSS |
|---|---|---|
| Price | $2.90 | $0.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 467.8K | 12.1K |
| Earning Date | 06-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,085,000.00 |
| Revenue This Year | $217,274.83 | $1.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.36 |
| 52 Week High | $13.19 | $1.86 |
| Indicator | VRAX | DSS |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 49.69 |
| Support Level | $0.19 | $0.50 |
| Resistance Level | $3.10 | $0.58 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 13.92 | 56.74 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
DSS Inc is operating a business focused on four operating segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Currently operates five distinct business lines that operate around the globe with primary operations in North America and Asia. Product packaging manufactures and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex three-dimensional direct mail solutions. The biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the Securities and Investment Management.